Cerebrospinal fluid biomarkers for neurodegenerative disorders
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/25736 |
Resumo: | Neurodegenerative diseases are one of the major world causes of morbidity and mortality, and giving the dramatic raise in life expectancy, they are reaching epidemic proportions. These disorders form a heterogeneous group, ranging from multi-factorial dementias to rare monogenic inherited proteopathies, but they all are progressive and so far lethal, since there are no disease-modifying therapies presently available. Therefore, major research efforts are in progress for developing effective therapies, but in order to achieve this goal there is an imperative need of consistent tools for diagnosis, prognosis and monitoring drug effects and efficacy. Biomarkers have the potential to respond to all these requirements and its research is a rapidly advancing field, supported by some cases of success for other diseases, in different fields like oncology and cardiology. Pathological alterations in the brain or central nervous system could be monitored by analysis of cerebrospinal fluid and several biomarkers in this fluid have been proposed. However, almost none have reached validation and for that reason they are still not used in clinical routine. Several problems regarding lack of longitudinal studies or reproducibility between reports are still waiting to be solved. In a near future this could happen by more intensive collaboration between research centers, industry and government in different countries, in joint initiatives. This review summarizes the most relevant CSF biomarker candidates for Alzheimer’s and Parkinson’s disease, Amyotrophic lateral sclerosis, Huntington’s and Machado Joseph disease. It also briefly passes through biomarker definitions and concepts, beyond the current limitations in this investigation area. |
id |
RCAP_acee89c0f9727873c45eb5b4bb671e17 |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/25736 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Cerebrospinal fluid biomarkers for neurodegenerative disordersDoenças neurodegenerativasBiomarcadoresNeurodegenerative diseases are one of the major world causes of morbidity and mortality, and giving the dramatic raise in life expectancy, they are reaching epidemic proportions. These disorders form a heterogeneous group, ranging from multi-factorial dementias to rare monogenic inherited proteopathies, but they all are progressive and so far lethal, since there are no disease-modifying therapies presently available. Therefore, major research efforts are in progress for developing effective therapies, but in order to achieve this goal there is an imperative need of consistent tools for diagnosis, prognosis and monitoring drug effects and efficacy. Biomarkers have the potential to respond to all these requirements and its research is a rapidly advancing field, supported by some cases of success for other diseases, in different fields like oncology and cardiology. Pathological alterations in the brain or central nervous system could be monitored by analysis of cerebrospinal fluid and several biomarkers in this fluid have been proposed. However, almost none have reached validation and for that reason they are still not used in clinical routine. Several problems regarding lack of longitudinal studies or reproducibility between reports are still waiting to be solved. In a near future this could happen by more intensive collaboration between research centers, industry and government in different countries, in joint initiatives. This review summarizes the most relevant CSF biomarker candidates for Alzheimer’s and Parkinson’s disease, Amyotrophic lateral sclerosis, Huntington’s and Machado Joseph disease. It also briefly passes through biomarker definitions and concepts, beyond the current limitations in this investigation area.2013info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttp://hdl.handle.net/10316/25736http://hdl.handle.net/10316/25736TID:201655284engVideira, Rita Margarida Almeida Santosinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-05-25T06:10:13Zoai:estudogeral.uc.pt:10316/25736Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:47:45.906743Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Cerebrospinal fluid biomarkers for neurodegenerative disorders |
title |
Cerebrospinal fluid biomarkers for neurodegenerative disorders |
spellingShingle |
Cerebrospinal fluid biomarkers for neurodegenerative disorders Videira, Rita Margarida Almeida Santos Doenças neurodegenerativas Biomarcadores |
title_short |
Cerebrospinal fluid biomarkers for neurodegenerative disorders |
title_full |
Cerebrospinal fluid biomarkers for neurodegenerative disorders |
title_fullStr |
Cerebrospinal fluid biomarkers for neurodegenerative disorders |
title_full_unstemmed |
Cerebrospinal fluid biomarkers for neurodegenerative disorders |
title_sort |
Cerebrospinal fluid biomarkers for neurodegenerative disorders |
author |
Videira, Rita Margarida Almeida Santos |
author_facet |
Videira, Rita Margarida Almeida Santos |
author_role |
author |
dc.contributor.author.fl_str_mv |
Videira, Rita Margarida Almeida Santos |
dc.subject.por.fl_str_mv |
Doenças neurodegenerativas Biomarcadores |
topic |
Doenças neurodegenerativas Biomarcadores |
description |
Neurodegenerative diseases are one of the major world causes of morbidity and mortality, and giving the dramatic raise in life expectancy, they are reaching epidemic proportions. These disorders form a heterogeneous group, ranging from multi-factorial dementias to rare monogenic inherited proteopathies, but they all are progressive and so far lethal, since there are no disease-modifying therapies presently available. Therefore, major research efforts are in progress for developing effective therapies, but in order to achieve this goal there is an imperative need of consistent tools for diagnosis, prognosis and monitoring drug effects and efficacy. Biomarkers have the potential to respond to all these requirements and its research is a rapidly advancing field, supported by some cases of success for other diseases, in different fields like oncology and cardiology. Pathological alterations in the brain or central nervous system could be monitored by analysis of cerebrospinal fluid and several biomarkers in this fluid have been proposed. However, almost none have reached validation and for that reason they are still not used in clinical routine. Several problems regarding lack of longitudinal studies or reproducibility between reports are still waiting to be solved. In a near future this could happen by more intensive collaboration between research centers, industry and government in different countries, in joint initiatives. This review summarizes the most relevant CSF biomarker candidates for Alzheimer’s and Parkinson’s disease, Amyotrophic lateral sclerosis, Huntington’s and Machado Joseph disease. It also briefly passes through biomarker definitions and concepts, beyond the current limitations in this investigation area. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/25736 http://hdl.handle.net/10316/25736 TID:201655284 |
url |
http://hdl.handle.net/10316/25736 |
identifier_str_mv |
TID:201655284 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133756056928256 |